POTASSIUM PHOSPHATES IN 0.9% SODIUM CHLORIDE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Phosphate supplementation to correct hypophosphatemia; acts as a buffer and is essential for cellular energy metabolism (ATP), bone mineralization, and acid-base balance.
| Metabolism | Phosphate is freely filtered by the glomerulus and reabsorbed in the proximal tubule; excess is excreted renally. No significant hepatic metabolism. |
| Excretion | Renal: >90% of phosphate is reabsorbed or excreted by the kidneys; potassium is primarily excreted renally. Fecal elimination accounts for <10% of total phosphate loss. |
| Half-life | Phosphate: 3-4 hours in healthy adults; prolonged with renal impairment. Potassium: short distribution half-life (~1-1.5 hours); no true terminal half-life due to tight regulation. |
| Protein binding | Phosphate: 10-15% bound to serum proteins (albumin and immunoglobulins). Potassium: <5% protein bound. |
| Volume of Distribution | Phosphate: 0.15-0.3 L/kg (primarily extracellular fluid). Potassium: 0.5-0.7 L/kg (distributes into intracellular space). |
| Bioavailability | Intravenous: 100% bioavailability. Oral (not applicable for this formulation): 60-70% for phosphate salts; potassium salts >90%. |
| Onset of Action | Intravenous: Hypophosphatemia correction begins within minutes; potassium repletion occurs over 1-2 hours. |
| Duration of Action | Duration of electrolyte normalization: phosphate levels correct over 6-12 hours post-infusion; potassium repletion sustained for 4-6 hours. |
| Molecular Weight | 136.09 |
IV: 2.5-5 mmol phosphate/kg body weight over 24 hours; typical dose 10-30 mmol phosphate over 4-6 hours; do not exceed 60 mmol phosphate/day.
| Dosage form | SOLUTION |
| Renal impairment | GFR <30 mL/min: initiate at 50% of standard dose and titrate based on serum phosphate and potassium levels; avoid if GFR <15 mL/min unless severe hypophosphatemia. |
| Liver impairment | No specific Child-Pugh based recommendations; use with caution in severe hepatic impairment due to potential for electrolyte disturbances. |
| Pediatric use | IV: 0.5-1 mmol phosphate/kg over 12-24 hours; monitor serum phosphate and potassium closely; do not exceed 5 mmol/kg/day. |
| Geriatric use | Initiate at lower end of dosing range; monitor renal function and serum electrolytes more frequently due to age-related decline in GFR. |
| 1st trimester | Potassium and phosphate are essential nutrients; use only if clearly needed. No known teratogenic risk at recommended doses. |
| 2nd trimester | Use if needed for electrolyte replacement. Monitor serum levels to avoid hyperkalemia or hyperphosphatemia. |
| 3rd trimester | Use if needed; avoid excessive doses due to risk of maternal electrolyte imbalance. No fetal harm reported. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium and phosphate readily cross the placenta; maintained within physiological range with maternal supplementation. |
| Breastfeeding | Potassium and phosphates are normal milk constituents. Intravenous administration may increase milk levels, but no adverse effects in infants reported. Use with caution and monitor infant electrolytes if mother receives high doses. |
| Lactation Rating | L2 - Safer |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second/third trimesters: may cause hypocalcemia, electrolyte imbalances in fetus; avoid prolonged use. |
| Fetal Monitoring | Monitor serum phosphate, potassium, calcium, magnesium, and renal function regularly. Monitor fetal heart rate and growth if used long-term. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data insufficient. |
■ FDA Black Box Warning
None
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHyperphosphatemiaHypocalcemia (due to risk of metastatic calcification)Severe renal impairment (e.g., oliguric renal failure)Addison's diseaseSevere burns (due to increased potassium release)
| Precautions | Hyperphosphatemia, especially in renal impairment, Hypocalcemia due to precipitation with calcium, Monitor serum calcium, phosphate, and renal function, Avoid extravasation (may cause tissue necrosis), Not for IV push; give as slow infusion |
| Food/Dietary | Avoid high-phosphate foods (e.g., dairy, nuts, seeds, whole grains, cola) and high-potassium foods (e.g., bananas, oranges, potatoes, spinach) unless prescribed. Limit intake of calcium-rich foods if calcium levels are low. |
| Clinical Pearls | Do not administer undiluted; must be infused via central line if concentration > 0.45% potassium phosphate. Monitor serum potassium, phosphate, calcium, and magnesium. Rate of infusion should not exceed 10 mmol/h of phosphate. Risk of hypocalcemia due to phosphate precipitation. Use with caution in renal impairment. |
| Patient Advice | This medication is given through a vein to restore phosphate and potassium levels. · Report any signs of infusion site pain, redness, or swelling. · Inform your healthcare provider if you experience muscle cramps, weakness, numbness, or tingling. · This medication may cause low calcium levels; report symptoms such as muscle spasms or confusion. · Do not consume additional potassium or phosphate supplements unless directed by your doctor. |
Loading safety data…